Abstract
Although platinum-pemetrexed chemotherapy remains the gold-standard for treatment of malignant pleural mesothelioma (MPM), to date we are still lacking true predictive biomarkers able to identify those patients who truly respond to chemotherapy. Aiming to overcome this problem, we previously performed microRNA expression profiling in tumour tissue of responders and non-responders to induction chemotherapy, which identified candidate predictive microRNAs. Candidates from this profiling are now investigated in vitro for their potential to alter the response of MPM cell lines to cisplatin and pemetrexed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
